News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RHEI Pharmaceuticals, Inc. to Market Oral Mucositis Treatment in China


9/30/2010 12:06:34 PM

September 30, 2010 -- RHEI Pharma has fleshed out its China marketing agreement with Access Pharmaceuticals for MuGard™, the latter company’s novel treatment for oral mucositis, a side effect of cancer treatment. MuGard is a ready-to-use mucoadhesive oral wound rinse and coating. RHEI specializes in bringing Western drugs to China. The original agreement between the two entities was signed almost three years ago. More details....

Read at BioSpace.com
Read at ChinaBio Today

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES